U.S. Markets closed

Analyzing Alexion Pharmaceuticals’ Product Performance

Kenneth Smith
Analyzing Alexion Pharmaceuticals’ Product Performance

Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma. Total Soliris sales increased from $755.4 million in the third quarter of 2017 to $888.0 million in the latest quarter. Its US sales increased from $307.6 million in the third quarter of 2017 to $404.5 million in the latest quarter. Its Europe sales increased from $248.4 million in the third quarter of 2017 to $262.1 million in the latest quarter.